Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa

Current Opinion in Oncology

Volumn 18, Issue 5, 2006, Pages 479-486

  Orem, Jackson ^a,d   Otieno, Mwanda W ^b   Remick, Scot C ^c  

^a MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UGANDA CANCER INSTITUTE   (Uganda)

Author keywords

African continent; AIDS; Developing world; Drug supply; Highly active antiretroviral therapy; Resource constrained setting

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AIDS RELATED MALIGNANCY; CHILDHOOD CANCER; CONJUNCTIVA; DEVELOPING COUNTRY; ENDEMIC DISEASE; EPIDEMIC; FEASIBILITY STUDY; HEALTH CARE AVAILABILITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SOCIOECONOMICS; SQUAMOUS CELL CARCINOMA;

AFRICA; HIV INFECTIONS; HUMANS; NEOPLASMS;

EID: 33746913896     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000239887.90665.10     Document Type: Review

References (56)

1. Orem J, Mwanda OW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16:468-476.
2. Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 1985; 2:849-852.
3. Joint United Nations Programme on HIV/AIDS. AIDS Epidemic Update: December 2005. http://www.unaids.org. [Accessed 21 April 2006]
4. WHO outlines three-pronged attack against AIDS epidemic. AIDS Weekly 2000; Feb 7:17.
5. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985-990. This updated publication reviews the spectrum of malignancies encountered in HIV-infected patients from the oldest and most authoritative cancer registry on the African continent.
6. Mwanda OW, Remick SC, Whalen C. Adult Burkitt's lymphoma in patients with and without human immunodefciency virus infection in Kenya. Int J Cancer 2001; 92:687-691.
7. Akinsete I, Akanmu AS, Okany CC. Spectrum of clinical diseases in HIV-infected adults at the Lagos University Teaching Hospital: a five-year experience [1992-1996]. Afr J Med Med Sci 1998; 27:147-151.
8. Nnoruka EN. Skin diseases in south-east Nigeria: a current perspective. Int J Dermatol 2005; 44:9-33. Recent report of emergence of Kaposi's sarcoma from a country in western Africa.
9. Amusa YB, Adediran IA, Akinpelu VO, et al. Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital. West Afr J Med 2005; 24:139-142. Recent report of emergence of Burkitt's lymphoma including HIV-infected patients from a country in western Africa.
10. Fadiora SO, Mabayoje VO, Aderoumu AO, et al. Generalised Burkitt's lymphoma involving both breasts - a case report. West Afr J Med 2005; 24:280-282.
11. Ziegler JL, Katongole-Mbidde E. Kaposi's sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer 1996; 65:200-203.
12. Mwanda OW, Fu P, Collea R, et al. Kaposi's sarcoma in patients with and without human immunodeficiency virus infection in a tertiary referral center in Kenya. Ann Trop Med Parasitol 2005; 99:81-91.
13. Ziegler J, Newton R, Bourboulia D, et al. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer 2003; 103:233-240.
14. Ziegler JL, Simonart T, Snoeck R. Kaposi's sarcoma, oncogenic viruses, and iron. J Clin Virol 2001; 20:127-130.
15. Boerma JT, Nunn AJ, Whitworth JA. Mortality impact of the AIDS epidemic: evidence from community sites in less developed countries. AIDS 1998; 12 (suppl):S3-S14.
16. Parkin DM, Garcia-Giannoli H, Raphael M, et al. Non-Hodgkin lymphoma in Uganda: a case-control study. AIDS 2000; 14:2929-2936.
17. Chirenje ZM. HIV and cancer of the cervix. Best Pract Res Clin Obstet Gynaecol 2005; 19:269-276.
18. Leroy V, Ladner J, De Clercq A, et al. Cervical dysplasia and HIV type 1 infection in African pregnant women: a cross sectional study, Kigali, Rwanda. The Pregnancy and HIV Study Group (EGE). Sex Transm Infect 1999; 75:103-106.
19. DeSilva DJ, Tumuluri K, Joshi N. Conjunctival squamous cell carcinoma: atypical presentation of HIV. Clin Exp Ophthalmol 2005; 33:419-420.
20. Pe'er J. Ocular surface squamous neoplasia. Ophthalmol Clin North Am 2005; 18:1-13. An authoritative review of a rare disease.
21. Tornesello ML, Waddell KM, Duraturo ML, et al. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detect Prev 2005; 29:501-509. Molecular pathogenesis study emanating from Uganda identifying potential risk factor for development of conjunctival carcinoma.
22. Ateenyi-Agaba C, Weiderpass E, Tommasino M, et al. Papillomavirus infection in the conjunctiva of individuals with and without AIDS: an autopsy series from Uganda. Cancer Lett 2005 [epub ahead of print]. Among the largest autopsy series including an analysis of HPV genotypes in the pathogenesis of this unqiue tumor ever published.
23. Pola EC, Masanganise R, Rusakaniko S. The trend of ocular surface squamous neoplasia among ocular surface tumour biopsies submitted for histology from Sekuru Kaguvi Eye Unit, Harare between 1996 and 2000. Cent Afr J Med 2003; 49:1-4.
24. Lavu E, Morewaya J, Maraka R, et al. Burkitt lymphoma in Papua New Guinea - 40 years on. Ann Trop Paediatr 2005; 25:191-197. Contemporary report of Burkitt's lymphoma in another region of the world with endemic disease.
25. Meremikwu MM, Ehiri JE, Nkanga DG, et al. Socioeconomic constraints to effective management of Burkitt's lymphoma in southeastern Nigeria. Trop Med Int Health 2005; 10:92-98. This paper reviews the implications of scarcity and challenges in treating Burkitt's lymphoma in Africa.
26. Mwanda OW, Rochford R, Moormann AM, et al. Burkitt's lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 2004; 81 (suppl):S68-S77.
27. Mwanda OW, Orem J, Remick SC, et al. Clinical characteristics of Burkitt's lymphoma from three regions in Kenya. East Afr Med J 2005; 82 (suppl):S135-S143. This study looks at the clinical features of childhood Burkitt's lymphoma in three distinct geographical regions of Kenya, suggesting that environmental factors are implicated in disease pathogenesis.
28. Kigula-Mugambe JB, Durosinmi-Etti FA. Radiotherapy in cancer management at Mulago Hospital, Kampala, Uganda. East Afr Med J 1996; 73:611-613.
29. World Health Organization. Minimum standard of care defined for HIV patients with cancer. Bull World Health Organ 2000; 80:176.
30. Fedorova A, Mlyavaya T, Alexeichik A, et al. Successful treatment of the HIV-associated Burkitt lymphoma in a three-year-old child. Pediatr Blood Cancer 2006; 47:92-93.
31. Lehmann C, Wyen C, Hoffman C, et al. Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma. HIV Med 2005; 6:51-53.
32. Fabiani M, Accorsi S, Aleni R, et al. Estimating HIV prevalence and the impact of HIV/AIDS on a Ugandan hospital by combining serosurvey data and hospital discharge records. J Acquir Immune Defic Syndr 2003; 34:62-66.
33. Orem J, Mwanda OW, Banura C, et al. Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev 2005; 29:133-145. The first report from the East Africa - Case Research Collaboration on AIDS malignancy, outlining the capacity-building strategy and pragmatism of research pursuits for improving healthcare delivery and clinical investigation into this aspect of the AIDS epidemic.
34. Hesseling PB, Broadhead R, Molyneux E, et al. Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol 2001; 19:2171-2178.
35. Hesseling P, Broadhead R, Mansvelt E, et al. The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer 2005; 44:245-250. Follow-up report to [34], in which modification to an intensive induction chemotherapy regimen for children with Burkitt's lymphoma, suitable for the resource-constrained setting, was still fraught with intolerable myelotoxicity and mortality.
36. Olowu WA, Elusiyan JB, Badejo SA, et al. Acute renal failure in African children with Burkitt's lymphoma: a comparison of two treatment regimens. Pediatr Blood Cancer 2006; 46:446-453.
37. Jaffar S, Govender T, Garrib A, et al. Antiretroviral treatment in resource-poor settings: public health research priorities. Trop Med Int Health 2005; 10:295-299.
38. Emanuel EJ, Wendler D, Killen J, et al. What makes clinical research in developing countries ethical? The benchmarks of ethical research. JID 2004; 189:930-937.
39. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005; 113:632-639. This paper addresses the complexities of evaluating palliative therapy for the most prevalent AIDS malignancy in Zimbabwe.
40. Grant E, Murray SA, Grant A, et al. A good death in rural Kenya? Listening to Meru patients and their families talk about care needs at the end of life. J Palliat Care 2003; 19:159-167.
41. Jagwe JG, Barnard D. The introduction of palliative care in Uganda. J Palliat Med 2002; 5:160-163.
42. Kikule E. A good death in Uganda: survey of needs for palliative care for terminally ill people in urban areas. BMJ 2003; 327:192-194.
43. Logie DE, Harding R. An evaluation of a morphine public health programme for cancer and AIDS pain relief in sub-Saharan Africa. BMC Public Health 2005; 5:82.
44. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA J Cancer Clin 2006; 56:69-83.
45. Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol 2005; 2:90-97. An authoritative review of the mechanisms of inflammation and cancer.
46. Kurokawa M, Ghosh SK, Ramos JC, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt's lymphoma. Blood 2005; 106:235-240.
47. Kurokawa M, Andela V, Ghosh S, et al. Zidovudine: a targeted therapy for endemic Burkitt's lymphoma. East Afr Med J 2005; 82:S150-S154.
48. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105:1891-1897.
49. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the prehighly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23:4430-4438.
50. Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477-8482.
51. Spina M, Simonelli C, Talamini R, et al. Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era [letter]. J Clin Oncol 2005; 23:8132-8133.
52. Stebbing J, Mandalia S, Palmieri C, et al. Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma [letter]. J Clin Oncol 2005; 23:8538-8540.
53. Freudenberg S, Palma P, Grobholz R, et al. HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum 2005; 48:1656-1659.
54. Mwanda OW, Whalen C, Remick SC, et al. Anatomical site predilections of non-Hodgkin's lymphoma in human immunodeficiency virus infection: a report on 54 cases. East Afr Med J 2004; 81 (suppl):S90-S96.
55. Rochford R, Feuer G, Orem J, et al. Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J 2005; 82 (suppl):S155-S160. This paper presents pathogenesis-based, hypothesis-driven testable nonmyelotoxic anticancer therapies suitable for evaluation in the resource-constrained setting. Several of the concepts presented are in the midst of preclinical and clinical evaluation.
56. Editorial. Africa 2005. Nature 2005; 433:669.